$CBNA

CHAIN BRIDGE BANCORP INC (CBNA): Results of Operations and Financial Condition

CHAIN BRIDGE BANCORP INC (CBNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cbna-earningsreleasexex991.htm EX-99.1 Document Exhibit 99.1 Chain Bridge Bancorp, Inc. Reports Second Quarter 2026 Financial Results McLean, Virginia — July 28, 2026 Chain Bridge Bancorp, Inc. (NYSE: CBNA) (the “Company”), the holding company for Chain Bridge Bank, N.A

Original reporting
Published Jul 28, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CBNA
Bullish
medium confidence
Mentioned
$CBNA
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CBNABullishMed
01

Why it matters

The release quantifies profitability (net income, EPS, ROE/ROA), funding (total deposits), and key income drivers (net interest income, deposit placement services). Traders can reassess valuation and near-term expectations based on these updated fundamentals.

02

Market read

Fresh earnings and balance-sheet metrics can move small-cap bank sentiment, especially if the market is focused on deposit growth and net interest income trajectory.

03

What to watch

Net interest margin was slightly lower year-over-year (3.43% vs 3.48%), and the excerpt does not show credit quality, provision trends, or noninterest income sustainability beyond deposit-related services.

Relevance 7/10Novelty 7/10Timing: after-hours earnings release filed July 28, 2026

Background

SEC Form 8-K Item 2.02 with Exhibit 99.1 reporting Chain Bridge Bancorp’s Q2 2026 and six-month results ended June 30, 2026.

Company-level read

Ticker impact

$CBNABullishMedium confidence
Context

Chain Bridge Bancorp reported Q2 2026 net income of $9.5M and EPS of $1.45, plus deposit growth to $2.0B at June 30.

Expected impact

Likely modest positive near-term bias if investors view the deposit-driven net interest income improvement as sustainable.

Evidence & confidence

The filing is a primary earnings release with multiple quantified drivers (net interest income up $2.1M QoQ, deposits up to $2.0B, book value per share rising). However, the excerpt does not include guidance or asset-quality details that could materially change risk perception.

Market effects

Adds datapoint on small-bank profitability sensitivity to deposit growth and net interest margin dynamics.

Limited to the company’s local banking footprint; no broader regional signal stated in the excerpt.

Minimal, as the disclosure is company-specific and not tied to global macro shocks beyond rates.

Counterpoint

Higher net interest income may be partly driven by deposit placement services and timing effects rather than durable core loan growth.

Key entities

  • Chain Bridge Bancorp, Inc.

    Holding company for Chain Bridge Bank, N.A., reporting Q2 2026 financial results on Form 8-K.

  • Chain Bridge Bank, N.A.

    Operating bank referenced as the source of the holding company’s performance.

Related articles

$MNDYHighAI 8/10

Why Monday.com Stock Popped in August

Monday.com (MNDY) stock rose 16% in August, despite initial investor concerns over its Q2 results. Revenue grew 22% YoY to $365M, and adjusted net income increased 13% to $65.6M. The company provided optimistic guidance for Q3 and 2026. A strong earnings report from Salesforce later in the month boosted investor sentiment in the CRM sector, benefiting Monday.com.

$AQSTMed

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.

$CRMDMedAI 8/10

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

CorMedix (CRMD) reported Q2 revenue of $101.9M, up from $39.7M a year ago, with net income of $26M. Management raised adjusted EBITDA guidance but kept full-year revenue guidance unchanged. DefenCath and the Melinta portfolio drove growth, with new supply agreements signed. The company expects to submit an sNDA for REZZAYO in Q3. Operating expenses increased due to Melinta's costs and R&D spending. Hedge fund ownership rose, while short interest remained high at 22.30%.

$CCSIMed

Consensus Cloud’s (CCSI) Buyback Doubles, But Growth Has A Catch

Consensus Cloud Solutions (CCSI) reported Q2 revenue of $91.4M, up 4.1%, and net income of $27.4M, up 31.7%. The board doubled its buyback authorization to $200M. Corporate segment revenue rose 9.3%, while the SoHo business declined 4.7%. Adjusted EBITDA was flat at $48.3M. The company reaffirmed its 2026 guidance and issued steady Q3 guidance.